Objective Interindividual clinical response to leukotriene modifiers is highly variable, and less efficacious than inhaled corticosteroids in treating asthma. Genetic variability in 5-lipoxygenase biosynthetic and receptor pathway gene loci may influence cysteinyl-leukotriene production and subsequent response to leukotriene modifiers.
Objective Interindividual clinical response to leukotriene modifiers is highly variable, and less efficacious than inhaled corticosteroids in treating asthma. Genetic variability in 5-lipoxygenase biosynthetic and receptor pathway gene loci may influence cysteinyl-leukotriene production and subsequent response to leukotriene modifiers.
Methods Using data from two clinical trials of 12-week duration, post-hoc analyses were performed in 174 patients randomized to montelukast. Associations between polymorphisms in 10 candidate genes (ALOX5, ALOX5AP, LTC4S, CYSLTR1, CYSLTR2, PLA2G4A, CYP2C9, CYP3A4, ADRB2, and NR3C1) and response to montelukast were modeled using change in morning peak expiratory flow and forced expiratory volume in 1 s (FEV 1 ) to define the response phenotype.
Results In our sample, eight out of 25 markers in 10 candidate genes were statistically associated with response to montelukast, with an estimated proportion of false discoveries of 16%. The strongest statistical evidence of clinically relevant pharmacogenetic effects peak expiratory flow were identified in CYSLTR2 (rs91227 and rs912278; P = 0.02 and P = 0.02, respectively) and ALOX5 (rs4987105 and rs4986832; P = 0.01 and P = 0.01, respectively). Patients with these variant genotypes, found in roughly 10-13% of patients, had an 18-25% improvement in peak expiratory flow. In contrast, the majority of patients with the wild-type alleles had only a marginal (8-10%) improvement.
Conclusions The overall mean response to montelukast may be skewed towards a response phenotype by a small subset ( < 15%) of asthma patients. CYSLTR2 and ALOX5 polymorphisms may predispose a minority of individuals to excessive cysteinyl-leukotriene concentrations, yielding a distinct asthma phenotype most likely to respond to leukotriene modifier pharmacotherapy. 
Introduction
Asthma is a chronic inflammatory airway disease partly characterized by increased numbers of activated eosinophils, mast cells, macrophages, and T lymphocytes in the airway mucosa and lumen. Cysteinyl-leukotrienes (CysLT) (leukotriene C 4 , D 4 , and E 4 ,), produced primarily from eosinophils and mast cells in the airways, are biologically active lipids that amplify and/or maintain inflammation by directing T-cell migration [1] . Leukotrienes are also mediators and modulators in the early phase of the asthmatic response to inhaled allergens [2] . Indeed, elevated leukotriene levels in the airways of patients with asthma, and induction of airflow obstruction upon leukotriene inhalation are well documented [3] [4] [5] .
A leukotriene-driven mechanism may represent a unique asthma phenotype requiring targeted pharmacotherapy.
Derivatives of arachidonic acid, leukotrienes are rapidly generated at de novo sites of inflammation via the 5-lipoxygenase (5-LO) biosynthetic pathway [5] . The pathway begins when inflammatory stimuli trigger the translocation of phospholipase A 2 which, in turn, releases arachidonic acid from cell membrane phospholipids. [6] . The CysLT 1 receptor mediates bronchoconstriction, plasma exudation, and mucus secretion, whereas CysLT 2 may play a role in smooth muscle cell proliferation [7] . Additionally, the relative concentration of local CysLT partly dictates the degree of receptor saturation and may alter the rate of exogenous ligand binding. Genetic variability in 5-LO pathway genes may influence CysLT production and subsequent response to leukotriene modifiers [8] [9] [10] [11] .
The leukotriene modifier montelukast is a selective antagonist of the leukotriene CysLT 1 receptor [12] .
Interindividual clinical response to leukotriene modifiers is highly variable, and less efficacious than inhaled corticosteroids in treating asthma [13] [14] [15] . The clinical, environmental, and genetic determinants of this heterogeneity in response are not understood. The ability to predict, by genetic means or otherwise, which patients favorably respond to leukotriene modifiers may improve clinical treatment guidelines.
This study was undertaken to evaluate associations between polymorphisms in key 5-LO biosynthetic pathway and receptor gene loci and pulmonary function measures in asthma patients randomized to montelukast in a clinical trial setting. Specifically, genes encoding for phospholipase A 2 (PLA2G4A), leukotriene C 4 synthase (LTC4S), CysLT 1 receptor (CYSLTR1), CysLT 2 receptor (CYSLTR2), 5-LO-activating protein (ALOX5AP), 5-LO (ALOX5), and two cytochrome P450 isoforms (CYP3A4 and CYP2C9) were evaluated. Additionally, the b 2 -adrenergic receptor (ADRB2) was assessed because mechanistically, the b 2 -adrenergic receptor may influence response to leukotriene modifiers via the so-called crosstalk between the activation of G s receptors causing airway smooth muscle relaxation, and G q -receptors that cause muscle contraction [16, 17] . Finally, the glucocorticoid receptor (NR3C1) was considered because glucocorticoids induce the upregulation of 5-LO.
Methods

Participants
Data from two identical studies in which DNA sampling was performed were used in these post-hoc analyses. The replicate trials, previously reported [18, 19] 
Genotyping
Genotyping was performed in a blinded manner at a central laboratory (GlaxoSmithKline) using collected blood samples on all participants for whom a sample was available. Previously characterized coding single nucleotide polymorphisms (SNPs) in the b 2 -adrenergic receptor gene [21] (HUGO nomenclature: ADRB2; Sequence Accession ID: NM_000024), phospholipase A 2 (PLA2G4A; NM_024420), leukotriene C 4 synthase (LTC4S; NM_000897), CysLT 1 receptor (CYSLTR1; NM_006639), CysLT 2 receptor (CYSLTR2; NM_020377), 5-LO-activating protein (ALOX5AP; NM_001629), 5-LO (ALOX5; NM_000698), glucocorticoid receptor (NR3C1; NM_000176), and cytochrome P450 isoforms (CYP3A4; NM_017460 and CYP2C9; NM_000771) were genotyped.
Markers were qualitatively selected on the basis of the available literature. A complete listing of polymorphisms evaluated is available online on the journal's website.
Statistical analysis
Changes in AM PEF and percentage predicted FEV 1 , measured over a 12-week study period, were used as proxy measures to quantify clinical response to montelukast. AM PEF and FEV 1 are well established diagnostic measures of assessing airway caliber in patients with asthma [22, 23] . An overall treatment effect was calculated by subtracting baseline value from the week 12 endpoint value.
Tests for genotype-phenotype associations were carried out using a total of 25 genotypic markers, against two dependent variables. Full models including additive and dominant genetic effects were estimated using two dummy variables G1 and G2, respectively. The value for G1 corresponded to the number of rare alleles and the value of G2 was a binary variable indicating heterozygosity status. Models with only additive genetic effects were also estimated. P values were estimated by fitting linear models and significance was initially assessed at the 5% level. Baseline measures were corrected for covariates that correlated strongly with their respective outcome. Baseline FEV 1 was correlated with log 10 percent reversibility at baseline (r = -0.34; P < 0.01). Baseline AM PEF was adjusted for age (r = -0.19; P = 0.01), sex (r = -0.68; P < 0.01), and height (r = 0.57; P < 0.01). Genotype classes with frequencies less than five were omitted. Following convention, the microsatellite marker in ALOX5 was coded as either the five repeat allele (wild-type) or the non-5 repeat alleles [10] .
The reduction of model error variance by the inclusion of additional covariates in the linear regression models may result in a more powerful test of genetic effects on treatment if, in fact, it could be verified that these covariates have no involvement in the effect of the treatment itself. If the covariates are indicators of treatment effect, then meaningful variation would be regressed out. We therefore ran models with and without covariate predictors including height, age, sex, reversibility, short-acting albuterol use, baseline respiratory measures, and investigator site, and observed no overall change in significant results. To examine whether significant results were due to the racial composition, we fitted linear regression models that included race as a predictor and compared them to models without race. Observed estimates were similar with the addition of the race in the model (results not shown).
To assess whether the SNPs with P values smaller than 0.05 were false discoveries, we estimated the positive false discovery rate (pFDR) [24, 25] . The pFDR can either be interpreted as an estimate of the proportion of false discoveries among the markers called significant or the probability that a significant marker is a false discovery. To calculate the pFDR, the proportion of tests for which the null hypothesis is true needs to be estimated. For this purpose, we used the 'lowest slope' estimate, known to be conservatively biased toward one [26] . In addition to its pleasant interpretation, pFDR methods appear fairly robust against the effects of correlated tests in general [25, [27] [28] [29] [30] [31] [32] . The intuitive explanation is that these methods estimate the ratio of false to total discoveries in a study. Correlated tests mainly increase the variance of these estimates. The FDR statistics themselves that are the means of these estimates tend to, however, remain similar.
In addition to the single-marker analyses, we tested for associations between our outcome measures and SNP haplotypes. To identify regions with low recombination needed for accurate haplotype analyses in samples of unrelated participants, the Haploview program (version 2.05) was used to analyze the 24 SNPs [33, 34] . Haplotype blocks were defined using the default block search procedure [35] . This criteria defines 'strong linkage disequilibrium (LD)' for marker pairs if the D 0 upper and lower 95% confidence bounds encompass 0.98 and 0.70, respectively. Evidence for historical recombination is given when the upper bound of D 0 is less than 0.9. A haplotype block is defined when less than 5% of marker pairs in a region show evidence for historical recombination. Makers with minor allele frequencies less than 5% were not included. Next, SNPs that were in the same block were analyzed together to study the association of the haplotypes within that block with each of the outcome variables. For these analyses, we used the UNPHASED (version 2.403) program [36] . UNPHASED does not attempt to assign haplotypes to individual participants, but uses an EM algorithm to estimate the frequencies of the different haplotypes and test whether the means differ across these haplotypes. A pooled variance estimate is used by UNPHASED, in part, to eliminate variance estimates on the basis of a few observations [36] . This assumption is commonly applied because it yields a more stable estimate of variance, and differences in variance are not of direct interest. Haplotypes with a frequency less than 2% were omitted from these analyses and the baseline measures were adjusted for correlated covariates as described above. Permutation testing was also performed for both single-marker and haplotype associations. The critical region that specifies a type I error rate of 5% was determined from the null distribution of the F statistic by 10 000 permutations of the response variable over participants.
Pharmacogenetics
Results
Baseline distributions
Demographic and baseline clinical characteristics for participants randomized to montelukast with available PGx sampling (n = 174; 41% of intent-to-treat sample) were similar to those observed in the general intent-totreat sample (ITT data previously published [18, 19] ). Baseline pulmonary function and other indicators of asthma severity were consistent across the two protocols ( Table 1) . Tests of homogeneity did not identify statistically significant departures for the primary endpoints and key demographics. Of the 174 participants with baseline data, eight individuals lacked both FEV 1 and AM PEF endpoint measures (n = 166 patients analyzed).
All measured genotypes were found to be in HardyWeinberg equilibrium as assessed by a w 2 goodness-of-fit test. At baseline, no phenotype-genotype associations at the 5% significance level were identified (data not shown).
Single-marker associations
Regression modeling was performed to test for associations between individual genotypes and response to montelukast, as defined by change from baseline in FEV 1 percentage predicted, and AM PEF ( Table 2) . Associations between at least one selected marker in ADRB2, NR3C1, ALOX5, and CYSLTR2 and at least one respiratory outcome measure were identified (Table 3) . Of note, several markers at each of these loci were found to be in LD, thus partially explaining the consistency of genotype-phenotype associations observed at each locus (Table 2 ).
Using change in AM PEF to estimate treatment effects, evidence for genotype-phenotype associations were identified for rs912277 and rs912278 in CYSLTR2 (P = 0.02 and P = 0.02, respectively) and for ALOX5 markers rs4987105 and rs4986832 (P = 0.01 and P = 0.01, respectively) ( Table 2 ). Response to montelukast was markedly higher in CYSLTR2 and ALOX5 genotypes with the variant allele ( Table 3) . P values for single-marker associations were also determined by permutation testing. The empirical critical region estimated for each marker response combination did not deviate from the model-based estimate (data not shown).
Admixture according to self-reported ethnicity was carefully evaluated. Admixture may lead to spurious genotype-outcome associations when both treatment effect and allele frequencies differ by ethnicity. We tested for each of these conditions and did not find any genotypeoutcome combinations for which both conditions were satisfied. All reported associations were therefore unlikely to be the result of the racial composition of the sample. To further examine whether statistically significant results were due to the racial composition, we fitted linear regression models that included race as a predictor. After statistically adjusting for ethnicity, all of our findings remained significant. Finally, we repeated our analysis in Caucasians only (79% of our total sample). In Caucasians, six of nine associations remained statistically significant under the full model (Supplemental Table 1 ).
Control of false discoveries
Focusing on the two main outcome measures (percent change FEV 1 and AM PEF), nine of the 50 association tests resulted in P values smaller than 0.05. The pFDR was calculated to estimate the proportion of false discoveries (using an a = 0.05, 2.5 false positives would be expected by chance). Using the conservative 'lowest slope' method [26] , the estimated number of true null hypotheses was 0.92 with a corresponding pFDR of 0.16. Thus, the expected proportion of false discoveries among the nine tests with P values less than 0.05 is 16% [32] .
Haplotype associations
Seven haplotype blocks, consistent with the observed LD patterns, were identified (Table 4) . Haplotype frequencies less than 2% were omitted. All analyses were repeated in self-identified Caucasians with similar haplotype block structures identified (data not shown).
Using the determined block structure, additional significance testing was performed to detect haplotypephenotype associations (Table 4) . Consistent with the single-marker results, ALOX5 and CYSLTR2 haplotypes were also associated with AM PEF. The observed ALOX5 haplotype was composed of a common haplotype (CG) and a relatively less frequent haplotype (TA). The less frequent haplotype (B19%) was associated with greater response defined by change in AM PEF from baseline (P = 0.003). Mean improvement in AM PEF was greatest among patients with the less frequent (B6%) CYSLTR2 haplotype (P = 0.02). P values empirically estimated from 10 000 permutations of participant responses remained essentially the same as theoretical values.
Additionally, for haplotypes with more than two alleles, we tested whether individual haplotypes differed from all other haplotypes grouped together within a block. The infrequent NR3C1 TT haplotype was found to have a significantly attentuated mean change in PEF as compared with the other haplotypes (P = 0.05), whereas the singlemarker analysis showed variant NR3C1 homozygotes to have the largest improvement in percent predicted FEV 1 . The common CYSLTR2 TT and TC haplotypes were each shown to have a significantly lower mean change in AM PEF (P = 0.007 and P = 0.04), observations that are consistent with the single-marker results.
Discussion
Our results identify genetic variants in the 5-LO pathway associated with therapeutic response to montelukast. In Number of ALOX5 alleles with five repeats of the Sp1-binding motif GGGCGG. 193 our sample of 166 asthma patients, eight out of 25 markers in 10 candidate genes were statistically associated with response to montelukast, with an estimated proportion of false discoveries of 31%. Specifically, using PEF and FEV 1 measures (tracked over a 12-week study period) to approximate the montelukast response phenotype, the strongest statistical evidence for clinically relevant associations were identified in CYSLTR2 and ALOX5 variants.
Pharmacogenetics of 5-lipoxygenase pathway
It has previously been shown that polymorphisms in ALOX5 are associated with clinical response to leukotriene modifier therapy. In one study of 221 asthma patients, the ALOX5 microsatellite was tested against response to ABT-761, an experimental leukotriene modifier [10] . Among predominant homozygotes (repeat length = 5; n = 64) and heterozygotes (n = 40), mean FEV 1 improved by approximately 18.8 ± 3.6 and 23.3 ± 6%, respectively. In comparison, variant homozygotes (non-5 repeats; n = 10) demonstrated a -1.2 ± 2.9% change. In a more recent study, the ALOX5 rs2115819 SNP was associated with change in FEV 1 and non-5 repeat carriers had higher rates of exacerbations among 61 Caucasian patients monitored for 6 months [37] . Conversely, a smaller study conducted in 52 patients with asthma did not identify any pharmacogenetic associations between ALOX5 and response to leukotriene modifier therapy [38] . The ALOX5 microsatellite was associated with response in the present study. We also observed the variant rs4987105 and rs4986832 homozygotes to be associated with improved AM PEF. The underlying mechanisms to explain these clinical observations remain poorly defined.
Although results were not as robust as for ALOX5, CYSLTR2 remains a plausible candidate from a biological perspective. CYSLTR2 encodes for a 346 amino acid protein with 38% amino acid identity to the CysLT 1 receptor [39] . It is believed that both CysLT 1 and CysLT 2 may be potent biological mediators in the pathophysiology of asthma by predisposing to bronchoconstriction, vascular hyperpermeability, and mucus hypersecretion in asthmatic patients. As such, it is hypothesized that leukotriene modifier therapy may be more efficacious among asthma patients with concentrated leukotriene activity [12, 40] . Mapped to 13q14, a chromosomal region linked to asthma, it has been shown that CYSLT2 is associated with: (i) susceptibility to asthma in Caucasians [8] and Japanese [41] ; (ii) atopic asthma in a founder population with a high prevalence of atopy [9] ; and (iii) aspirin intolerance in Korean patients with asthma [42] . Moreover, in comparison to wild-type CYSLTR2, CYSLTR2 coding variants at positions A601G [13] and M202V [12] demonstrated reduced leukotriene potency as measured by calcium flux assays. If CYLTR2 polymorphisms do indeed predispose individuals to a leukotriene-based asthma phenotype, then our results are consistent with the notion that leukotriene modifier therapies are more efficacious among a small subset of patients with concentrated leukotriene activity (i.e. those patients harboring CYSLTR2 variants). This is also consistent with the observations of Szefler and colleagues [43] who report that some asthmatic children (B22% of sample) who demonstrated an improvement in FEV 1 of 7.5% or greater had elevated median leukotriene concentration. The direct functional significance of the CYSLTR2 SNPs we evaluated is unknown. Systematic analysis of the haplotype structure and sequence variation of CYSLTR2 will be needed to identify the actual casual variant(s) predisposing to asthma and/or influencing response to pharmacotherapy.
The net effect of signaling events from G s (e.g. b 2 -adrenergic receptor activation ultimately results in a decrease of intracellular Ca 2 + ) and G q (e.g. cysteinyl leukotriene receptor activation increase intracellular Ca 2 + stores) on airway smooth muscle cells, muscle tone, and airway responsiveness is a critical and dynamic process responsible for maintaining homeostasis. This study is supported by emerging in-vitro data, which suggests that the propensity for one G-protein coupled receptor signal to alter another, or the so-called cross-talk between G as -receptors and G aq -receptors, may partly underly pharmacogenetic variation of b-agonists and ADRB2 polymorphisms [44, 45] . Considering the postulated interdependence of G as and G aq -receptor signaling, genetic variability influencing the G a signaling may also hold clinical relevance for leukotriene modifier therapy. Although statistical associations between ADRB2 polymorphisms and response to montelukast were identified, these observations did not appear to have clinical significance.
LTC4S has been evaluated as a pharmacogenetic locus because variability in this gene may be associated with enhanced production of CysLTs, thus sustaining airway inflammation and bronchoconstriction in patients with asthma [11] . In contrast to previous reports, we did not find evidence for association between LTC4S and response to montelukast.
A potential limitation of this study includes the incomplete coverage of polymorphisms in the candidate gene loci evaluated. Untyped polymorphisms, or haplotypes, may have functional effects on gene function, and thus be more informative in characterizing pharmacogenetic associations. Consequently, we cannot rule out a gene if no association was observed in our sample. A second potential limitation is multiple comparisons. As traditional multiple testing corrections tend to be overly conservative, the FDR was calculated. The estimated proportion of false discoveries in our study is 16%, suggesting that at least six of the eight genotypephenotype associations are not spurious statistical associations owing to multiple comparisons. Larger replication studies, including asthma patients with a more broad representative spectrum of asthma severity and control, will be needed to confirm our findings. The underlying drug mechanism(s) of action are complex, and it is likely that polymorphisms in other genes contribute to the heterogeneity of response. Given the many gene products involved in the pharmacodynamic and pharmacokinetic pathways of asthma drugs [46] , the modest effect sizes reported herein are consistent with what would be expected for a polygenic trait. Once a panel of pharmacogenetic loci are identified, potential clinical applications of PGx for asthma management strategies will require prospective testing.
In summary, our results suggest that variant CYSLTR2 and ALOX5 polymorphisms may enhance response to montelukast. These markers were found in roughly 10-13% of patients enrolled on our trials. Asthma genetic studies, animal models, and in-vitro findings suggest that these loci predispose to allergic respiratory disorders and may correlate with an asthma phenotype most likely to respond to leukotriene modifier pharmacotherapy. Although inhaled corticosteroids alone or coadministered with long-acting b-agonists are, on average, more efficacious than montelukast in treating asthma patients [43, [47] [48] [49] [50] [51] , further elucidation of 5-LO pharmacogenetics may serve to identify the subset of asthma patients most likely to benefit from leukotriene modifier therapy.
